Antisense oligonucleotides (ASOs) are being developed as treatments for rare genetic disorders such as SCN2A. What are they and how do they work? To help gain a better understanding of ASOs and their role we talk to Dr Stanley Crooke, founder of Ionis. Hosted by Kris Pierce and David Cunnington, parents of Will, who has SCN2A. Leave a review and subscribe via Apple Podcasts.  You can also find SCN2A Insights on Spotify, and Google Podcasts or in your podcast app Links American Epilepsy Society meeting Summary of ASO presentations at AES Dr Ana Mignorance - @CNSDrugHunter on Twitter Ionis  Webinar on ASO treatment for gain of function SCN2A See omnystudio.com/listener for privacy information.

Ver todos los episodios